Candel Therapeutics, Inc.
CADL
$5.02
$0.6013.58%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 21.52% | 76.23% | |||
| Gross Profit | -21.52% | -76.23% | |||
| SG&A Expenses | 12.88% | 2.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.16% | 37.48% | |||
| Operating Income | -18.16% | -37.48% | |||
| Income Before Tax | -134.97% | -165.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -134.97% | -165.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -134.97% | -165.00% | |||
| EBIT | -18.16% | -37.48% | |||
| EBITDA | -18.99% | -38.68% | |||
| EPS Basic | -120.52% | -163.68% | |||
| Normalized Basic EPS | -120.45% | -163.68% | |||
| EPS Diluted | -120.52% | -171.62% | |||
| Normalized Diluted EPS | -120.45% | -169.12% | |||
| Average Basic Shares Outstanding | 6.61% | 2.00% | |||
| Average Diluted Shares Outstanding | 6.61% | -5.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||